The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by Wells Fargo on August 12, 2025. The analyst firm set a price target for $3.00 expecting STRO to fall to within 12 months (a possible -69.97% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by Wells Fargo, and Sutro Biopharma maintained their equal-weight rating.

The last upgrade for Sutro Biopharma Inc happened on June 16, 2025 when Piper Sandler raised their price target to $2. Piper Sandler previously had a neutral for Sutro Biopharma Inc.

The last downgrade for Sutro Biopharma Inc happened on March 17, 2025 when HC Wainwright & Co. changed their price target from $12 to $2 for Sutro Biopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on August 12, 2025 so you should expect the next rating to be made available sometime around August 12, 2026.

While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a maintained with a price target of $4.00 to $3.00. The current price Sutro Biopharma (STRO) is trading at is $9.99, which is out of the analyst’s predicted range.